Search Technologies

Researchers from NCI and Rudgers University developed  methods of detecting abnormal cells in a sample using the spatial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the spatial position of one or more genes within the nucleus of a cell. The National Cancer Institute seeks parties interested in collaborative research to co-develop diagnostic methods for detection of cancer using spatial genome organization.

The National Cancer Institute (NCI) seeks licensees for a preclinical orthotopic mouse model of glioblastoma multiforme (GBM).

Device is used to guide a stream of oxygen or carbon dioxide over a dish of cells during fluorescence microscopy. Invention includes the 3D printing software to create the device. The device makes it possible to easily provide a steady source of oxygen or carbon dioxide to cells while operating a fluorescent microscope to oxidize fluorophores for later visualization in electron microscopy. NCI seeks commercial partners to license this technology.

This invention is a research tool for measuring protective antibody responses against Human Papilloma Viruses (HPV). The invention is available for non-exclusive license.

This technology is a new generation of rationally designed chelating agents that improve the complexation of Zirconium-89 for PET imaging of cancers.

The National Cancer Institute (NCI) has a human epidermal growth factor receptor- (EGFR) driven tumor mouse model of lung adenocarcinoma available for licensing.

The National Cancer Institute''s Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers.